[HTML][HTML] Antibody targeting of E3 ubiquitin ligases for receptor degradation
Most current therapies that target plasma membrane receptors function by antagonizing
ligand binding or enzymatic activities. However, typical mammalian proteins comprise …
ligand binding or enzymatic activities. However, typical mammalian proteins comprise …
Antibody targeting of E3 ubiquitin ligases for receptor degradation
H Marei, WTK Tsai, YS Kee, K Ruiz, J He, C Cox… - …, 2022 - ui.adsabs.harvard.edu
Most current therapies that target plasma membrane receptors function by antagonizing
ligand binding or enzymatic activities. However, typical mammalian proteins comprise …
ligand binding or enzymatic activities. However, typical mammalian proteins comprise …
Antibody targeting of E3 ubiquitin ligases for receptor degradation
H Marei, WTK Tsai, YS Kee, K Ruiz, J He, C Cox, T Sun… - paper.sciencenet.cn
Most current therapies that target plasma membrane receptors function by antagonizing
ligand binding or enzymatic activities. However, typical mammalian proteins comprise …
ligand binding or enzymatic activities. However, typical mammalian proteins comprise …
Antibody targeting of E3 ubiquitin ligases for receptor degradation
H Marei, WTK Tsai, YS Kee, K Ruiz, J He, C Cox… - …, 2022 - pubmed.ncbi.nlm.nih.gov
Most current therapies that target plasma membrane receptors function by antagonizing
ligand binding or enzymatic activities. However, typical mammalian proteins comprise …
ligand binding or enzymatic activities. However, typical mammalian proteins comprise …
Antibody targeting of E3 ubiquitin ligases for receptor degradation
H Marei, WTK Tsai, YS Kee, K Ruiz, J He, C Cox, T Sun… - Nature, 2022 - ideas.repec.org
Most current therapies that target plasma membrane receptors function by antagonizing
ligand binding or enzymatic activities. However, typical mammalian proteins comprise …
ligand binding or enzymatic activities. However, typical mammalian proteins comprise …
Antibody targeting of E3 ubiquitin ligases for receptor degradation
H Marei, WTK Tsai, YS Kee, K Ruiz, J He, C Cox… - Nature, 2022 - econpapers.repec.org
Most current therapies that target plasma membrane receptors function by antagonizing
ligand binding or enzymatic activities. However, typical mammalian proteins comprise …
ligand binding or enzymatic activities. However, typical mammalian proteins comprise …
Antibody targeting of E3 ubiquitin ligases for receptor degradation.
H Marei, WK Tsai, YS Kee, K Ruiz, J He, C Cox, T Sun… - Nature, 2022 - europepmc.org
Most current therapies that target plasma membrane receptors function by antagonizing
ligand binding or enzymatic activities. However, typical mammalian proteins comprise …
ligand binding or enzymatic activities. However, typical mammalian proteins comprise …
[HTML][HTML] Antibody targeting of E3 ubiquitin ligases for receptor degradation
H Marei, WTK Tsai, YS Kee, K Ruiz, J He, C Cox, T Sun… - Nature, 2022 - ncbi.nlm.nih.gov
Most current therapies that target plasma membrane receptors function by antagonizing
ligand binding or enzymatic activities. However, typical mammalian proteins comprise …
ligand binding or enzymatic activities. However, typical mammalian proteins comprise …
Antibody targeting of E3 ubiquitin ligases for receptor degradation.
H Marei, WK Tsai, YS Kee, K Ruiz, J He, C Cox, T Sun… - Nature, 2022 - europepmc.org
Most current therapies that target plasma membrane receptors function by antagonizing
ligand binding or enzymatic activities. However, typical mammalian proteins comprise …
ligand binding or enzymatic activities. However, typical mammalian proteins comprise …